Pentoxifylline in the treatment of intermittent claudication of the lower limbs. 1984

T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness

Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States. Tests were performed on 128 cases, including 42 who took pentoxifylline (600 mg by mouth daily, increased stepwise to 1200 mg daily at the end of one month) and 40 who took placebo for 24 weeks. Twenty-five patients on pentoxifylline and 21 on placebo were dropped from the study for reasons unrelated to the drug. Walking ability on a treadmill was increased significantly after 2 weeks and remained so throughout the study in the pentoxifylline vs. the placebo group. Ability to walk until first experiencing intermittent claudication was a more sensitive index than the maximum ability to walk. The drug did not cause changes in blood pressure or in heart rate. Other than mild nausea, there were no significant side effects.

UI MeSH Term Description Entries
D007383 Intermittent Claudication A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE. Claudication, Intermittent
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010431 Pentoxifylline A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. Agapurin,BL-191,Oxpentifylline,Pentoxil,Torental,Trental,BL 191,BL191
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012907 Smoking Willful or deliberate act of inhaling and exhaling SMOKE from burning substances or agents held by hand. Smoking Behaviors,Smoking Habit,Behavior, Smoking,Behaviors, Smoking,Habit, Smoking,Habits, Smoking,Smoking Behavior,Smoking Habits
D013805 Theobromine 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)

Related Publications

T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
July 1994, Angiology,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
October 1991, La Revue du praticien,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
November 1987, The New Zealand medical journal,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
August 1987, The New Zealand medical journal,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
September 2015, The Cochrane database of systematic reviews,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
October 1987, The New Zealand medical journal,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
October 2020, The Cochrane database of systematic reviews,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
January 1985, Annals of internal medicine,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
November 1984, The Medical letter on drugs and therapeutics,
T Reich, and B C Cutler, and B Y Lee, and J M Porter, and F A Reichle, and J T Scogin, and D E Strandness
January 2012, The Cochrane database of systematic reviews,
Copied contents to your clipboard!